PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.
Snapshot
- Overview – PharmaVitae forecasts Shionogi’s revenue to remain flat through 2029, with royalties from its HIV franchise accounting for the largest proportion of revenues.
- Key themes – [1] Longer-listed products have been able to maintain profits in the short term, such as royalties from Crestor, with expected decreases still to come [2] With forecasts for Xofluza, Cymbalta, and Intuniv being cut significantly, Shionogi is looking to adjust its business strategy for these assets moving forward.
Model updates (30 October 2020)
- HIV royalties forecast adjusted lower due to trends seen from Juluca, Dovato, and Triumeq
- Vyvanse forecast adjusted lower due to continued launch trends in Japan.
Model updates (3 February 2020)
- Xofluza forecast adjusted lower due to wholesalers having leftover inventory from last year’s flu season, and concerns about its effectiveness for all forms of influenza
- Cymbalta forecast adjusted lower due to poor performance in first-line chronic lower back pain
- Intuniv forecast adjusted lower due to being unable to capture share from Concerta or Strattera.
Model updates (30 October 2019)
- Cefiderocol US and EU launch delayed.
Model updates (14 August 2019)
- Actair forecast adjusted lower due to company guidance
- Cefiderocol forecast adjusted lower in Japan due to reported sales, and US, EU, and RoW launch delayed
- Crestor forecast adjusted higher due to company guidance
- Crestor Royalties forecast adjusted higher due to company guidance
- Cymbalta forecast adjusted higher due to company guidance
- Esbriet/Pirespa forecast adjusted higher due to company guidance, and patent expiry added
- Intuniv forecast adjusted higher due to an immediate increase in market share for adult patients
- Mulpleta forecast adjusted lower due to drop in uptake
- Symproic forecast adjusted higher in Japan due to company guidance.
Table of Contents
Company Background
Company Overview
Key Metrics
SWOT Analysis
Key Drug & Company Information
Company Comparison
Company Forecast
Prescription Pharmaceuticals Sales Outlook
Branded Drug Outlook
Launch Profile Outlook
Therapy Area Outlook
Regional Sales Outlook
Lifecycle Analysis
Company Profile
Marketed & Pipeline Drugs
Recent Events & Analyst Opinions
Upcoming Catalysts
Recent Insights
Clinical Trial Overview
Clinical Trial Snapshot
Clinical Trials by Country
Clinical Trials by Status and Phase
Clinical Trials by Drug